Egypt Diabetes Drugs and Devices Market Size (2024 - 2029)

The market size for diabetes drugs and devices in Egypt is projected to experience growth over the forecast period, driven by increased awareness and the need for regular monitoring and management of blood glucose levels, particularly highlighted by the COVID-19 pandemic. The pandemic underscored the importance of diabetes care devices, as individuals with diabetes faced heightened risks and complications due to COVID-19. Egypt's high prevalence of diabetes, influenced by lifestyle changes, further contributes to the expanding demand for diabetes management solutions, thereby impacting the market size positively.

Home Market Analysis Healthcare Research Device Drug Combination Research Egypt Diabetes Drugs and Devices Market Market Size

Market Size of Egypt Diabetes Drugs and Devices Industry

Egypt Diabetes Drugs and Devices Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2018 - 2022
CAGR 3.00 %

Major Players

Egypt Diabetes Drugs and Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Egypt Diabetes Drugs and Devices Market Analysis

Egypt's diabetes drugs and devices market size is estimated at USD 0.7 billion in the current year. The market is expected to reach USD 0.9 billion in five years, registering a CAGR of more than 3.1% during the forecast period.

The COVID-19 pandemic positively impacted the growth of the diabetes care device market in Egypt. Patients having diabetes and infected with COVID-19 might suffer from high blood glucose, unusual variations in glucose levels, as well as diabetic issues. Diabetes among people with COVID-19 resulted in notable increases in severity and mortality regarding COVID-19 for those with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), mainly when linked to inadequate glycemic control. The growing awareness of the onset of hyperglycemia and new-onset diabetes (both T1DM and T2DM) in relation to COVID-19 and their associated worse outcomes has highlighted the need for regular monitoring and management of a patient's blood glucose. As such, a pandemic emergency has emphasized the importance of diabetes care devices through remote care.

Egypt is the ninth state regarding Diabetes prevalence globally. Currently, as specified by IDF, about 18. 4 % of the adult population in Egypt has diabetes. Over 11 % of the Egyptian population is diagnosed with Type-2 diabetes, as per Egypt's Adolescence Organization for Vitality Advancement. 73 million grown-ups (20-79) had diabetes in the IDF MENA location last year. This figure is estimated to boost to 95 million in seven years

Egypt has witnessed an alarming boost in the prevalence of diabetes; in recent years, the rate of diabetes is at an all-time high, mainly because of the way of life alterations. Diabetes is connected with a few vitality complications. Patients with diabetes demand a few daily corrections to maintain nominal blood glucose levels, such as administering extra insulin or ingesting different carbohydrates by observing their blood glucose levels. Diabetes poses an emerging medical care burden across the nation.

Thus, the above factors are expected to drive market growth over the forecast period.

Egypt Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. to control blood sugar levels, insulin must be given several times daily, such as when eating or drinking. many people with type 2 diabetes also need to take antidiabetic drugs. these drugs include diabetes medications and injections such as insulin. diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices ( management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). the report offers the value (in USD) and volume (in unit) for the above segments.

Devices
Monitoring Devices
Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices
Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs
Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region Or Segment?
Customize Now

Egypt Diabetes Drugs and Devices Market Size Summary

The diabetes drugs and devices market in Egypt is experiencing significant growth, driven by the increasing prevalence of diabetes and the rising demand for effective management solutions. The market is characterized by a growing awareness of the importance of regular blood glucose monitoring and management, particularly in the context of the COVID-19 pandemic, which has underscored the need for advanced diabetes care devices. Egypt ranks ninth globally in diabetes prevalence, with a substantial portion of the adult population affected by the condition. This has led to a surge in the adoption of continuous glucose monitoring (CGM) systems, which are becoming increasingly popular due to their ability to provide real-time glucose readings and trends. Technological advancements in CGM devices are expected to further propel market growth, as they offer enhanced precision and convenience for patients managing diabetes.

The market landscape is also shaped by socio-economic factors, with access to healthcare services being a critical issue, particularly in rural areas where healthcare facilities are limited. Financial constraints further complicate access to necessary diabetes care supplies for many Egyptians. Despite these challenges, the government is making efforts to improve patient access through various initiatives. The market is competitive, with major players like Abbott, Medtronic, and Novo Nordisk actively engaging in mergers, acquisitions, and partnerships to strengthen their market positions. These companies are investing heavily in research and development to innovate and meet the evolving needs of diabetic patients in Egypt. Additionally, collaborations, such as those between Becton, Dickinson, and Company and Biocorp, are aimed at enhancing adherence to self-administered drug therapies, further supporting the market's expansion.

Explore More

Egypt Diabetes Drugs and Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Dynamics

      1. 1.2.1 Market Drivers

      2. 1.2.2 Market Restraints

    3. 1.3 Porter's Five Forces Analysis

      1. 1.3.1 Bargaining Power of Suppliers

      2. 1.3.2 Bargaining Power of Consumers

      3. 1.3.3 Threat of New Entrants

      4. 1.3.4 Threat of Substitute Products and Services

      5. 1.3.5 Intensity of Competitive Rivalry

  2. 2. Market Segmentation (Market Size by Value - USD)

    1. 2.1 Devices

      1. 2.1.1 Monitoring Devices

        1. 2.1.1.1 Self-monitoring Blood Glucose Devices

        2. 2.1.1.2 Continuous Blood Glucose Monitoring

      2. 2.1.2 Management Devices

        1. 2.1.2.1 Insulin Pump

        2. 2.1.2.2 Insulin Syringes

        3. 2.1.2.3 Insulin Cartridges

        4. 2.1.2.4 Disposable Pens

    2. 2.2 Drugs

      1. 2.2.1 Oral Anti-Diabetes Drugs

      2. 2.2.2 Insulin Drugs

      3. 2.2.3 Combination Drugs

      4. 2.2.4 Non-Insulin Injectable Drugs

Egypt Diabetes Drugs and Devices Market Size FAQs

The Egypt Diabetes Drugs and Devices Market is projected to register a CAGR of greater than 3% during the forecast period (2024-2029)

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the Egypt Diabetes Drugs and Devices Market.

Egypt Diabetes Drugs and Devices Market Report Snapshots

Egypt Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)